Stack Financial Management Inc cut its holdings in shares of Zoetis Inc (NYSE:ZTS) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 319,851 shares of the company’s stock after selling 12,652 shares during the quarter. Zoetis accounts for 3.2% of Stack Financial Management Inc’s investment portfolio, making the stock its 7th largest position. Stack Financial Management Inc owned approximately 0.07% of Zoetis worth $29,286,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the business. Janney Montgomery Scott LLC raised its holdings in shares of Zoetis by 7.2% in the 3rd quarter. Janney Montgomery Scott LLC now owns 122,765 shares of the company’s stock valued at $11,240,000 after purchasing an additional 8,279 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Zoetis by 13.5% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 693,577 shares of the company’s stock valued at $63,504,000 after purchasing an additional 82,535 shares in the last quarter. Gulf International Bank UK Ltd raised its holdings in shares of Zoetis by 5.6% in the 3rd quarter. Gulf International Bank UK Ltd now owns 162,888 shares of the company’s stock valued at $14,914,000 after purchasing an additional 8,600 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its holdings in shares of Zoetis by 2.9% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 78,570 shares of the company’s stock valued at $7,194,000 after purchasing an additional 2,200 shares in the last quarter. Finally, WINTON GROUP Ltd raised its holdings in shares of Zoetis by 55.6% in the 3rd quarter. WINTON GROUP Ltd now owns 3,789 shares of the company’s stock valued at $347,000 after purchasing an additional 1,354 shares in the last quarter. Institutional investors own 89.68% of the company’s stock.
In other Zoetis news, CEO Juan Ramon Alaix sold 135,000 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total transaction of $12,359,250.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Catherine A. Knupp sold 46,816 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the transaction, the insider now directly owns 81,640 shares in the company, valued at $7,416,177.60. The disclosure for this sale can be found here. Insiders have sold a total of 200,201 shares of company stock worth $18,306,772 over the last three months. 0.35% of the stock is currently owned by insiders.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period last year, the firm posted $0.65 EPS. Zoetis’s revenue for the quarter was up 9.9% on a year-over-year basis. As a group, equities analysts expect that Zoetis Inc will post 3.1 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be given a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.53%. The ex-dividend date is Monday, November 19th. Zoetis’s payout ratio is currently 20.83%.
A number of equities research analysts have recently weighed in on ZTS shares. Jefferies Financial Group set a $96.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Friday, July 13th. Cantor Fitzgerald set a $98.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Friday, July 27th. Bank of America lifted their price target on shares of Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. BMO Capital Markets reiterated a “hold” rating and set a $82.00 price target on shares of Zoetis in a research note on Thursday, August 2nd. Finally, Morgan Stanley lifted their price target on shares of Zoetis from $87.00 to $92.00 and gave the stock a “hold” rating in a research note on Friday, August 3rd. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $93.19.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.